Advertisement

Increasing Kidney Transplant Availability: Live Donation, Paired Donation, and Transplant Across ABO and HLA Barriers

  • Lavjay Butani
Reference work entry
Part of the Organ and Tissue Transplantation book series (OTT)

Abstract

Living donor renal transplantation affords numerous benefits to the recipient and donor alike. However, living donor renal transplantation continues to lag behind deceased donor transplants in the USA for a variety of reasons. These include a lack of awareness among patients, patients’ families, health-care professionals, and the public about its benefits, sociocultural factors leading to mistrust of the health-care system, a significant financial burden on potential donors, and lastly biomedical factors that hinder living donation such as ABO/HLA incompatibility among donor-recipient dyads. Understanding the nuances of these barriers is critical in order to address and overcome them. This chapter explores these impediments and the strategies that are being employed to combat them and thereby increase living organ donation. Strategies discussed include ways to educate stakeholders about the logistics and the benefits of living donor renal transplantation, removing financial disincentives for organ donors, developing systems to enable donor exchanges and altruistic donation, and biomedical strategies to overcome the ABO/HLA incompatibility barrier.

Keywords

Living donation Desensitization Intravenous immunoglobulin Plasmapheresis Immunoadsorption Rituximab Paired donor exchange 

References

  1. Ahmad N, Ahmed K, Khan MS, Calder F, Mamode N, Taylor J, Koffman G (2008) Living-unrelated donor renal transplantation: an alternative to living-related donor transplantation? Ann R Coll Surg Engl 90(3):247–250.  https://doi.org/10.1308/003588408X261636 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Aikawa A, Kawamura T, Shishido S, Saito K, Takahashi K, members AB-ITC (2014) ABO-incompatible living-donor pediatric kidney transplantation in Japan. Clinics (Sao Paulo) 69(Suppl 1):22–27CrossRefGoogle Scholar
  3. Alkhunaizi AM, de Mattos AM, Barry JM, Bennett WM, Norman DJ (1999) Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 67(10):1319–1324CrossRefPubMedGoogle Scholar
  4. Axelrod DA, McCullough KP, Brewer ED, Becker BN, Segev DL, Rao PS (2010) Kidney and pancreas transplantation in the United States, 1999–2008: the changing face of living donation. Am J Transplant 10(4 Pt 2):987–1002.  https://doi.org/10.1111/j.1600-6143.2010.03022.x CrossRefPubMedGoogle Scholar
  5. Balhara KS, Kucirka LM, Jaar BG, Segev DL (2012) Disparities in provision of transplant education by profit status of the dialysis center. Am J Transplant 12(11):3104–3110.  https://doi.org/10.1111/j.1600-6143.2012.04207.x CrossRefPubMedGoogle Scholar
  6. Ballow M (2014) Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol 14(6):509–515.  https://doi.org/10.1097/ACI.0000000000000116 CrossRefPubMedGoogle Scholar
  7. Becker LE, Siebert D, Susal C, Opelz G, Leo A, Waldherr R, Macher-Goeppinger S, Schemmer P, Schaefer SM, Klein K, Beimler J, Zeier M, Schwenger V, Morath C (2015) Outcomes following ABO-incompatible kidney transplantation performed after desensitization by nonantigen-specific immunoadsorption. Transplantation 99(11):2364–2371.  https://doi.org/10.1097/TP.0000000000000753 CrossRefPubMedGoogle Scholar
  8. Bentall A, Cornell LD, Gloor JM, Park WD, Gandhi MJ, Winters JL, Chedid MF, Dean PG, Stegall MD (2013) Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 13(1):76–85.  https://doi.org/10.1111/j.1600-6143.2012.04291.x CrossRefPubMedGoogle Scholar
  9. Bock GH, Conners CK, Ruley J, Samango-Sprouse CA, Conry JA, Weiss I, Eng G, Johnson EL, David CT (1989) Disturbances of brain maturation and neurodevelopment during chronic renal failure in infancy. J Pediatr 114(2):231–238CrossRefPubMedGoogle Scholar
  10. Boulware LE, Ratner LE, Sosa JA, Cooper LA, LaVeist TA, Powe NR (2002) Determinants of willingness to donate living related and cadaveric organs: identifying opportunities for intervention. Transplantation 73(10):1683–1691CrossRefPubMedGoogle Scholar
  11. Bryan CF, Nelson PW, Shield CF, Warady BA, Winklhofer FT, Murillo D, Wakefield MR (2007) Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. Am J Transplant 7(5):1181–1184.  https://doi.org/10.1111/j.1600-6143.2007.01750.x CrossRefPubMedGoogle Scholar
  12. Brynger H, Rydberg L, Samuelsson B, Blohme I, Lindholm A, Sandberg L (1983) Renal transplantation across a blood group barrier – ‘A2’ kidneys to ‘O’ recipients. Proc Eur Dial Transplant Assoc 19:427–431PubMedGoogle Scholar
  13. Butani L, Perez RV (2011) Effect of pretransplant dialysis modality and duration on long-term outcomes of children receiving renal transplants. Transplantation 91(4):447–451.  https://doi.org/10.1097/TP.0b013e318204860b PubMedGoogle Scholar
  14. Buyan N, Turkmen MA, Bilge I, Baskin E, Haberal M, Bilginer Y, Mir S, Emre S, Akman S, Ozkaya O, Fidan K, Alpay H, Kavukcu S, Sever L, Ozcakar ZB, Dogrucan N (2010) Quality of life in children with chronic kidney disease (with child and parent assessments). Pediatr Nephrol 25(8):1487–1496.  https://doi.org/10.1007/s00467-010-1486-1 CrossRefPubMedGoogle Scholar
  15. Cereb N, Kim HR, Ryu J, Yang SY (2015) Advances in DNA sequencing technologies for high resolution HLA typing. Hum Immunol 76(12):923–927.  https://doi.org/10.1016/j.humimm.2015.09.015 CrossRefPubMedGoogle Scholar
  16. Chehade H, Rotman S, Matter M, Girardin E, Aubert V, Pascual M (2015) Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics 135(2):e551–e555.  https://doi.org/10.1542/peds.2014-2275 CrossRefPubMedGoogle Scholar
  17. Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD (2015) Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 15(5):1293–1302.  https://doi.org/10.1111/ajt.13168 CrossRefPubMedGoogle Scholar
  18. Cravedi P, Heeger PS (2014) Complement as a multifaceted modulator of kidney transplant injury. J Clin Invest 124(6):2348–2354.  https://doi.org/10.1172/JCI72273 CrossRefPubMedPubMedCentralGoogle Scholar
  19. de Klerk M, Witvliet MD, Haase-Kromwijk BJ, Weimar W, Claas FH (2008) A flexible national living donor kidney exchange program taking advantage of a central histocompatibility laboratory: the Dutch model. Clin Transpl 8:69–73Google Scholar
  20. Dorje C, Mjoen G, Strom EH, Holdaas H, Jenssen T, Oyen O, Akkok CA, Cvancarova M, Midtvedt K, Reisaeter AV (2015) One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts. Clin Transplant 29(3):268–276.  https://doi.org/10.1111/ctr.12515 CrossRefPubMedPubMedCentralGoogle Scholar
  21. Duquesnoy RJ (2014) HLA epitope based matching for transplantation. Transpl Immunol 31(1):1–6.  https://doi.org/10.1016/j.trim.2014.04.004 CrossRefPubMedGoogle Scholar
  22. Duquesnoy RJ, Gebel HM, Woodle ES, Nickerson P, Baxter-Lowe LA, Bray RA, Claas FH, Eckels DD, Friedewald JJ, Fuggle SV, Gerlach JA, Fung JJ, Kamoun M, Middleton D, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A (2015a) High-resolution HLA typing for sensitized patients: advances in medicine and science require us to challenge existing paradigms. Am J Transplant 15(10):2780–2781.  https://doi.org/10.1111/ajt.13376 CrossRefPubMedGoogle Scholar
  23. Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, Woodle ES, Bray RA, Claas FH, Eckels DD, Friedewald JJ, Fuggle SV, Gebel HM, Gerlach JA, Fung JJ, Middleton D, Nickerson P, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A (2015b) Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant 15(4):923–930.  https://doi.org/10.1111/ajt.13167 CrossRefPubMedGoogle Scholar
  24. Flechner SM, Leeser D, Pelletier R, Morgievich M, Miller K, Thompson L, McGuire S, Sinacore J, Hil G (2015) The incorporation of an advanced donation program into kidney paired exchange: initial experience of the National Kidney Registry. Am J Transplant 15(10):2712–2717.  https://doi.org/10.1111/ajt.13339 CrossRefPubMedGoogle Scholar
  25. Gillespie A, Hammer H, Bass SB, Ouzienko V, Obradovic Z, Urbanski M, Browne T, Silva P (2015) Attitudes towards living donor kidney transplantation among urban African American hemodialysis patients: a qualitative and quantitative analysis. J Health Care Poor Underserved 26(3):852–872.  https://doi.org/10.1353/hpu.2015.0087 CrossRefPubMedGoogle Scholar
  26. Gloor JM, Cosio FG, Rea DJ, Wadei HM, Winters JL, Moore SB, DeGoey SR, Lager DJ, Grande JP, Stegall MD (2006) Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 6(8):1841–1847.  https://doi.org/10.1111/j.1600-6143.2006.01416.x CrossRefPubMedGoogle Scholar
  27. Gore JL, Danovitch GM, Litwin MS, Pham PT, Singer JS (2009) Disparities in the utilization of live donor renal transplantation. Am J Transplant 9(5):1124–1133.  https://doi.org/10.1111/j.1600-6143.2009.02620.x CrossRefPubMedGoogle Scholar
  28. Gore JL, Singer JS, Brown AF, Danovitch GM (2012) The socioeconomic status of donors and recipients of living unrelated renal transplants in the United States. J Urol 187(5):1760–1765.  https://doi.org/10.1016/j.juro.2011.12.112 CrossRefPubMedGoogle Scholar
  29. Hidalgo G, Tejani C, Clayton R, Clements P, Distant D, Vyas S, Baqi N, Singh A (2001) Factors limiting the rate of living-related kidney donation to children in an inner city setting. Pediatr Transplant 5(6):419–424CrossRefPubMedGoogle Scholar
  30. Higgins R, Lowe D, Hathaway M, Williams C, Lam FT, Kashi H, Tan LC, Imray C, Fletcher S, Chen K, Krishnan N, Hamer R, Daga S, Edey M, Zehnder D, Briggs D (2011) Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. Transplantation 92(8):900–906.  https://doi.org/10.1097/TP.0b013e31822dc38d CrossRefPubMedGoogle Scholar
  31. Higgins RM, Daga S, Mitchell DA (2015) Antibody-incompatible kidney transplantation in 2015 and beyond. Nephrol Dial Transplant 30(12):1972–1978.  https://doi.org/10.1093/ndt/gfu375 CrossRefPubMedGoogle Scholar
  32. Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, Russell PS, Colvin RB (2012) A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 12(2):313–321.  https://doi.org/10.1111/j.1600-6143.2011.03836.x CrossRefPubMedGoogle Scholar
  33. Idica A, Kaneku H, Everly MJ, Trivedi HL, Feroz A, Vanikar AV, Shankar V, Trivedi VB, Modi PR, Khemchandani SI, Dave SD, Terasaki PI (2008) Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin Transpl 6:229–239Google Scholar
  34. Jackson AM, Kraus ES, Orandi BJ, Segev DL, Montgomery RA, Zachary AA (2015) A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int 87(2):409–416.  https://doi.org/10.1038/ki.2014.261 CrossRefPubMedGoogle Scholar
  35. Jordan SC, Vo AA (2013) Evolving concepts in desensitization. Clin Transpl 19:285–292Google Scholar
  36. Jordan SC, Vo AA (2014) Donor-specific antibodies in allograft recipients: etiology, impact and therapeutic approaches. Curr Opin Organ Transplant 19(6):591–597.  https://doi.org/10.1097/MOT.0000000000000128 CrossRefPubMedGoogle Scholar
  37. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, Milliner D, Graff R, Steiner R, Ciancio G, Sahney S, Light J (2004) Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 15(12):3256–3262.  https://doi.org/10.1097/01.ASN.0000145878.92906.9F CrossRefPubMedGoogle Scholar
  38. Jordan SC, Choi J, Vo A (2015) Kidney transplantation in highly sensitized patients. Br Med Bull 114(1):113–125.  https://doi.org/10.1093/bmb/ldv013 CrossRefPubMedGoogle Scholar
  39. Kurella Tamura M, Li S, Chen SC, Cavanaugh KL, Whaley-Connell AT, McCullough PA, Mehrotra RL (2014) Educational programs improve the preparation for dialysis and survival of patients with chronic kidney disease. Kidney Int 85(3):686–692.  https://doi.org/10.1038/ki.2013.369 CrossRefPubMedGoogle Scholar
  40. Lo P, Sharma A, Craig JC, Wyburn K, Lim W, Chapman JR, Palmer SC, Strippoli GF, Wong G (2015) Preconditioning therapy in ABO-incompatible living kidney transplantation: a systematic review and meta-analysis. Transplantation.  https://doi.org/10.1097/TP.0000000000000933 Google Scholar
  41. Loupy A, Hill GS, Jordan SC (2012) The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 8(6):348–357.  https://doi.org/10.1038/nrneph.2012.81 CrossRefPubMedGoogle Scholar
  42. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Fremeaux-Bacchi V, Mejean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X (2013) Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 369(13):1215–1226.  https://doi.org/10.1056/NEJMoa1302506 CrossRefPubMedGoogle Scholar
  43. Martin DE, White SL (2015) Financial incentives for living kidney donors: are they necessary? Am J Kidney Dis 66(3):389–395.  https://doi.org/10.1053/j.ajkd.2015.03.041 CrossRefPubMedGoogle Scholar
  44. May LJ, Yeh J, Maeda K, Tyan DB, Chen S, Kaufman BD, Bernstein D, Rosenthal DN, Hollander SA (2014) HLA desensitization with bortezomib in a highly sensitized pediatric patient. Pediatr Transplant 18(8):E280–E282.  https://doi.org/10.1111/petr.12347 CrossRefPubMedGoogle Scholar
  45. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, Zachary AA, Segev DL (2011) Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 365(4):318–326.  https://doi.org/10.1056/NEJMoa1012376 CrossRefPubMedGoogle Scholar
  46. Nelson PW, Helling TS, Shield CF, Beck M, Bryan CF (1992) Current experience with renal transplantation across the ABO barrier. Am J Surg 164(5):541–544, discussion 544–545CrossRefPubMedGoogle Scholar
  47. Nelson PW, Hughes TM, Beck ML, Warady BA, Aeder MI, Helling TS, Landreneau MD, Luger AM, Pierce GE, Ross G et al (1996) Stratification and successful transplantation of patients awaiting ABO-incompatible (A2 into B and O) transplantation by A-isoagglutinin-titer phenogroup. Transplant Proc 28(1):221–223PubMedGoogle Scholar
  48. Nguyen S, Gallay B, Butani L (2014) Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen. Pediatr Transplant 18(5):463–468.  https://doi.org/10.1111/petr.12274 CrossRefPubMedGoogle Scholar
  49. Okumi M, Toki D, Nozaki T, Shimizu T, Shirakawa H, Omoto K, Inui M, Ishida H, Tanabe K (2015) ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am J Transplant.  https://doi.org/10.1111/ajt.13502 PubMedGoogle Scholar
  50. Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA (2014) Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 98(8):857–863.  https://doi.org/10.1097/TP.0000000000000298 CrossRefPubMedGoogle Scholar
  51. Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141(2):191–197.  https://doi.org/10.1067/mpd.2002.125910 CrossRefPubMedGoogle Scholar
  52. Park WD, Grande JP, Ninova D, Nath KA, Platt JL, Gloor JM, Stegall MD (2003) Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 3(8):952–960CrossRefPubMedGoogle Scholar
  53. Rees MA, Kopke JE, Pelletier RP, Segev DL, Rutter ME, Fabrega AJ, Rogers J, Pankewycz OG, Hiller J, Roth AE, Sandholm T, Unver MU, Montgomery RA (2009) A nonsimultaneous, extended, altruistic-donor chain. N Engl J Med 360(11):1096–1101.  https://doi.org/10.1056/NEJMoa0803645 CrossRefPubMedGoogle Scholar
  54. Revollo JY, Cuffy MC, Abu Jawdeh BG, Paterno F, Girnita A, Brailey P, Alloway RR, Woodle ES (2015) Case report: successful living donor kidney transplantation in a highly human leukocyte antigen-sensitized recipient with a positive cytotoxic crossmatch using bortezomib-based desensitization without intravenous immunoglobulin. Transplant Proc 47(7):2254–2257.  https://doi.org/10.1016/j.transproceed.2015.05.028 CrossRefPubMedGoogle Scholar
  55. Rodrigue JR, Schold JD, Mandelbrot DA (2013) The decline in living kidney donation in the United States: random variation or cause for concern? Transplantation 96(9):767–773.  https://doi.org/10.1097/TP.0b013e318298fa61 CrossRefPubMedGoogle Scholar
  56. Rodrigue JR, Kazley AS, Mandelbrot DA, Hays R, LaPointe Rudow D, Baliga P (2015) Living donor kidney transplantation: overcoming disparities in live kidney donation in the US-recommendations from a consensus conference. Clin J Am Soc Nephrol 10(9):1687–1695.  https://doi.org/10.2215/CJN.00700115 CrossRefPubMedPubMedCentralGoogle Scholar
  57. Salter ML, Orandi B, McAdams-DeMarco MA, Law A, Meoni LA, Jaar BG, Sozio SM, Kao WH, Parekh RS, Segev DL (2014) Patient- and provider-reported information about transplantation and subsequent waitlisting. J Am Soc Nephrol 25(12):2871–2877.  https://doi.org/10.1681/ASN.2013121298 CrossRefPubMedPubMedCentralGoogle Scholar
  58. Smith JM, Martz K, Blydt-Hansen TD (2013) Pediatric kidney transplant practice patterns and outcome benchmarks, 1987–2010: a report of the North American Pediatric Renal Trials and Collaborative Studies. Pediatr Transplant 17(2):149–157.  https://doi.org/10.1111/petr.12034 CrossRefPubMedGoogle Scholar
  59. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, Cosio FG, Gandhi MJ, Kremers W, Gloor JM (2011) Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11(11):2405–2413.  https://doi.org/10.1111/j.1600-6143.2011.03757.x CrossRefPubMedGoogle Scholar
  60. Tan JC, Gordon EJ, Dew MA, LaPointe Rudow D, Steiner RW, Woodle ES, Hays R, Rodrigue JR, Segev DL (2015) Living donor kidney transplantation: facilitating education about live kidney donation-recommendations from a consensus conference. Clin J Am Soc Nephrol 10(9):1670–1677.  https://doi.org/10.2215/CJN.01030115 CrossRefPubMedPubMedCentralGoogle Scholar
  61. Tierney J, Shaffer D (2015) Transplantation of ABO A2 kidneys into O recipients: do IgM anti-A1 titers matter? Clin Transplant 29(4):379–382.  https://doi.org/10.1111/ctr.12527 CrossRefPubMedGoogle Scholar
  62. Tong A, Chapman JR, Wong G, Craig JC (2014) Perspectives of transplant physicians and surgeons on reimbursement, compensation, and incentives for living kidney donors. Am J Kidney Dis 64(4):622–632.  https://doi.org/10.1053/j.ajkd.2014.02.019 CrossRefPubMedGoogle Scholar
  63. Tushla L, Rudow DL, Milton J, Rodrigue JR, Schold JD, Hays R (2015) Living-donor kidney transplantation: reducing financial barriers to live kidney donation-recommendations from a consensus conference. Clin J Am Soc Nephrol 10(9):1696–1702.  https://doi.org/10.2215/CJN.01000115 CrossRefPubMedPubMedCentralGoogle Scholar
  64. Tyden G, Kumlien G, Berg UB (2011) ABO-incompatible kidney transplantation in children. Pediatr Transplant 15(5):502–504.  https://doi.org/10.1111/j.1399-3046.2011.01480.x CrossRefPubMedGoogle Scholar
  65. Valentini RP, Nehlsen-Cannarella SL, Gruber SA, Mattoo TK, West MS, Lang C, Imam AA (2007) Intravenous immunoglobulin, HLA allele typing and HLA matchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients. Pediatr Transplant 11(1):77–81.  https://doi.org/10.1111/j.1399-3046.2006.00617.x CrossRefPubMedGoogle Scholar
  66. Valli PV, Puga Yung G, Fehr T, Schulz-Huotari C, Kaup N, Gungor T, Ambuhl P, Weber M, Schanz U, Seebach JD, Stussi G (2009) Changes of circulating antibody levels induced by ABO antibody adsorption for ABO-incompatible kidney transplantation. Am J Transplant 9(5):1072–1080.  https://doi.org/10.1111/j.1600-6143.2009.02579.x CrossRefPubMedGoogle Scholar
  67. Van Arendonk KJ, Orandi BJ, James NT, Segev DL, Colombani PM (2013) Living unrelated renal transplantation: a good match for the pediatric candidate? J Pediatr Surg 48(6):1277–1282.  https://doi.org/10.1016/j.jpedsurg.2013.03.023 CrossRefPubMedGoogle Scholar
  68. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC (2008) Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359(3):242–251.  https://doi.org/10.1056/NEJMoa0707894 CrossRefPubMedGoogle Scholar
  69. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, Reinsmoen NL, Villicana R, Jordan SC (2010) Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 89(9):1095–1102.  https://doi.org/10.1097/TP.0b013e3181d21e7f CrossRefPubMedGoogle Scholar
  70. Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, Villicana R, Mackowiak J, Jordan SC (2013) Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation 95.(6):852–858.  https://doi.org/10.1097/TP.0b013e3182802f88 CrossRefPubMedGoogle Scholar
  71. Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, Ge S, Toyoda M, Kahwaji J, Peng A, Villicana R, Jordan SC (2014) Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation 98(3):312–319.  https://doi.org/10.1097/TP.0000000000000064 CrossRefPubMedGoogle Scholar
  72. Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J, Toyoda M, Ge S, Haas M, Puliyanda D, Reinsmoen N, Peng A, Villicana R, Jordan SC (2015a) A phase I/II trial of the interleukin-6 receptor specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation.  https://doi.org/10.1097/TP.0000000000000741 PubMedCentralGoogle Scholar
  73. Vo AA, Sinha A, Haas M, Choi J, Mirocha J, Kahwaji J, Peng A, Villicana R, Jordan SC (2015b) Factors predicting risk for antibody-mediated rejection and graft loss in highly human leukocyte antigen sensitized patients transplanted after desensitization. Transplantation 99(7):1423–1430.  https://doi.org/10.1097/TP.0000000000000525 CrossRefPubMedGoogle Scholar
  74. Vo AA, Zeevi A, Choi J, Cisneros K, Toyoda M, Kahwaji J, Peng A, Villicana R, Puliyanda D, Reinsmoen N, Haas M, Jordan SC (2015c) A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 99(2):299–308.  https://doi.org/10.1097/TP.0000000000000592 CrossRefPubMedGoogle Scholar
  75. Wahrmann M, Haidinger M, Kormoczi GF, Weichhart T, Saemann MD, Geyeregger R, Kikic Z, Prikoszovich T, Drach J, Bohmig GA (2010) Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 89(11):1385–1390.  https://doi.org/10.1097/TP.0b013e3181d9e1c0 CrossRefPubMedGoogle Scholar
  76. Warren PH, Gifford KA, Hong BA, Merion RM, Ojo AO (2014) Development of the National Living Donor Assistance Center: reducing financial disincentives to living organ donation. Prog Transplant 24(1):76–81.  https://doi.org/10.7182/pit2014593 CrossRefPubMedPubMedCentralGoogle Scholar
  77. Waterman AD, Morgievich M, Cohen DJ, Butt Z, Chakkera HA, Lindower C, Hays RE, Hiller JM, Lentine KL, Matas AJ, Poggio ED, Rees MA, Rodrigue JR, LaPointe Rudow D (2015) Living donor kidney transplantation: improving education outside of transplant centers about live donor transplantation-recommendations from a consensus conference. Clin J Am Soc Nephrol 10(9):1659–1669.  https://doi.org/10.2215/CJN.00950115 CrossRefPubMedPubMedCentralGoogle Scholar
  78. Woodle ES, Shields AR, Ejaz NS, Sadaka B, Girnita A, Walsh RC, Alloway RR, Brailey P, Cardi MA, Abu Jawdeh BG, Roy-Chaudhury P, Govil A, Mogilishetty G (2015) Prospective iterative trial of proteasome inhibitor-based desensitization. Am J Transplant 15(1):101–118.  https://doi.org/10.1111/ajt.13050 CrossRefPubMedGoogle Scholar
  79. Zenios SA, Woodle ES, Ross LF (2001) Primum non nocere: avoiding harm to vulnerable wait list candidates in an indirect kidney exchange. Transplantation 72(4):648–654CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pediatric NephrologyUniversity of California Davis Children’s HospitalSacramentoUSA

Personalised recommendations